Clinical Trials Logo

Clinical Trial Summary

The aim of this study was to investigate the changes in the scalp bacterial and fungal microbiota in subjects afflicted with a scalp seborrheic dermatitis (SSD) during a 2% ketoconazole-based treatment followed by a maintenance phase (1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo versus its vehicle).


Clinical Trial Description

Seborrheic dermatitis is a chronic, recurrent, cutaneous inflammatory condition that causes erythema and skin flaking, sometimes appearing as macules or plaques with dry white or moist oily scales. In general, this condition affects patients in good general health. In adults, it commonly occurs in areas with high concentrations of sebaceous glands. The scalp is the most frequently affected area (80-90 percent of the cases). These plaques are usually masked by the hair but covered by abundant dandruff, very visible on the head and even on the clothes. In the severe forms, the dandruff plaques develop into "helmets": they then cover tufts of hair and can cause them to fall. On the scalp, the lesions may range from mild desquamation to brownish crusts affixed to the skin and hair. Some patients report pruritus, particularly if the scalp is affected. Secondary bacterial infection may occur, aggravating erythema and exudate and causing local discomfort. Dandruff is regarded as a mild non-inflammatory form of seborrheic dermatitis. The cause of seborrheic dermatitis is not well understood, but its occurrence appears to be related to the proliferation of commensal Malassezia species. Seborrheic dermatitis often has a substantial negative impact on quality of life and is associated with direct and indirect medical costs. The primary goals of therapy for seborrheic dermatitis are to clear the visible signs of disease and reduce bothersome symptoms, especially pruritus. Seborrheic dermatitis of the scalp is most conveniently treated with shampoos containing antifungal agents, corticosteroids, or keratolytic agent. They have been shown to be effective in the treatment of seborrheic dermatitis, but recurrence is common and that ongoing treatment may be necessary. For this study, the choice of the treatment against seborrheic dermatitis was set to ketoconazole, which is a common treatment that shows efficacy. The purpose of this study is to find a way to ameliorate the quality of life of subjects with seborrheic dermatitis. This trial will evaluate the antidandruff maintenance effect of a 1% selenium sulfide/1% salicylic acid-based shampoo (cosmetic shampoo) versus its vehicle during a 8 week application duration, after the subjects were treated with a classic antifungal treatment for seborrheic dermatitis (in this study, the treatment will be a ketoconazole-based antifungal treatment for 4 weeks in adults with light to moderate seborrheic dermatitis). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04057950
Study type Interventional
Source L'Oreal
Contact
Status Completed
Phase N/A
Start date June 1, 2019
Completion date March 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Recruiting NCT01012453 - A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema N/A
Completed NCT00375713 - Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema Phase 3
Completed NCT00001150 - Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers N/A
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Withdrawn NCT04154033 - Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone Phase 2
Completed NCT02979210 - Infant Fecal Insult Study N/A
Completed NCT02615912 - A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants N/A
Withdrawn NCT01125761 - Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis Phase 3
Withdrawn NCT00746382 - A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM) Phase 2
Terminated NCT00176956 - Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients Phase 3
Completed NCT05001139 - Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam N/A
Completed NCT00801502 - Salmon in Pregnancy Study N/A
Completed NCT00005781 - Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles N/A
Completed NCT05324618 - Tacrolimus Versus Hydrocortisone in Atopic Dermatitis Phase 4
Completed NCT04826471 - Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam N/A
Recruiting NCT05891743 - Prevalence of Skin Sensitization and Dermatitis Among Epoxy-exposed Workers in the Wind Turbine Industry.